aramchol + vitamin d

**Aramchol + vitamin D** is an investigational combination therapy of Aramchol, a synthetic fatty acid-bile acid conjugate, and supplemental vitamin D3. Aramchol is a small-molecule inhibitor of stearoyl-CoA desaturase 1 (SCD1), targeting hepatic fibrosis and metabolic dysfunction. Vitamin D3 is a key steroid hormone known for its anti-inflammatory, metabolic, and immunomodulatory roles. This combination is being studied for nonalcoholic fatty liver disease (NAFLD) and liver fibrosis, where Aramchol directly targets fibrogenesis and improves lipid metabolism, while vitamin D supplementation addresses vitamin D deficiency that exacerbates hepatic inflammation and fibrosis. Both components are administered orally and are designed to address distinct but complementary pathological processes in NAFLD/NASH patients, particularly those with vitamin D deficiency. The combination has been investigated in a Phase IIa trial led by Mount Sinai and Galmed Pharmaceuticals, with the primary outcome being reduction in liver fibrosis and secondary metabolic and imaging endpoints. Galmed Pharmaceuticals is pursuing a composition of matter patent on this combination therapy[1].

Other names

vitamin d3